Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
14 Cards in this Set
- Front
- Back
Cite the percentage of abdominal pain complaints in primary care which subside without a definitive diagnosis being reached.
|
40-50%
|
|
If you have an acute abdomen, what would you see for:
1) History 2) Physical exam 3) Appearance 4) Abdominal exam 5) Labs 6) Diagnostic test sensitivies/specificities |
Acute onset, trauma, no prior abdominal complaints. Pain severity may or may not
help differentiate "surgical" from “non-surgical” abdomen. Vital signs: especially fever, low B.P., high pulse Lying in one position (hurts to move or cough due to peritoneal irritation). Distention or obstructive signs; tenderness to percussion or rebound, esp. if localized (perforation or peritoneal irritation); blood on gastric aspirate or rectal exam; include pelvic exam in women Normal urinalysis; acute anemia or left shift on CBC; include HCG in Women Discuss with the students the relative sensitivity of various radiographic imaging studies for the diagnosis of acute appendicitis. Abdominal plain films (low sensitivity and specificity) Ultrasound (sensitivity 75-90%, specificity 86-100%) Spiral CT (sensitivity 90-100%, specificity 91-99%) |
|
Construct a plan to manage the potentially surgical abdomen by timely observation and
appropriate consultation. |
Consult surgeon early if any positive findings, above; co-manage with repeat exams,
judicious pain meds, repeat CBC's (increasing WBC’s?, decreasing hct?); start IV, type and cross-match blood p.r.n.; keep patient n.p.o. |
|
Construct a stepped approach to the management of patients with gastroesophageal
reflux disease, based upon evidence based medicine as well as cost effectiveness |
A. Lifestyle modification - (elevated head of bed 6 inches, decrease fat intake, stop
smoking, decrease weight, avoid large meals or aggravating foods avoid, avoid recumbency for three hours post-prandially.) B. Antacid or H2-blocker - as needed. C. Scheduled dose of H2-blocker, proton pump inhibitor, and/or a prokinetic agent, e.g., metoclopramide (Reglan) for 8-12 weeks. Consider endoscopy if severe or no response. D. Maintain therapy with H2-blocker or proton pump inhibitor. E. Surgical intervention for refractory cases. |
|
List and evaluate four tests for H. pylori.
|
Serology (whole blood or serum serology is cost effective initial approach in
symptomatic and at risk symptomatic patients; should confirm the test with a different method if pre-test probability is low. C13 or C14 Urea Breath Test (UBT). The sensitivity and specificity of UBT is approximately 88 to 95 and 95 to 100 percent, respectively. False positive results are uncommon. To prevent false negative results, the patient should be off antibiotics for at least four weeks and off proton pump inhibitors for at least two weeks. Stool Antigen (if patient not on PPI or taking bismuth). Endoscopic Gastric Biopsy (reserved for patients undergoing EGD). |
|
List two causes of peptic ulcer disease and discuss treatment options.
|
NSAID use - avoid NSAIDS. Treat with H2-blockers or proton pump inhibitor. Treat
H.pylori if present (see below). H.pylori - combined treatment with omeprazole, bismuth, metronidazole, clarithromycin and/or amoxicillin. Several regimens available using 2-3 of the above drugs for 1-2 weeks duration (e.g., lansoprazole 30mg + amoxicillin 1gm + clarithromycin 500mg all bid X 14 day |
|
Differentiate chronic from acute diarrhea
|
2 weeks = chronic. (compare with cough 4 weeks = chronic)
|
|
List symptoms that help differentiate viral from bacterial acute diarrhea.
|
Viral is more likely associated with vomiting, watery diarrhea; and no fever, no blood
or pus in the stool |
|
Discuss rehydration in the treatment of dehydration due to acute diarrhea.
|
Oral rehydration therapy (ORT); in children, also continue calorie intake (especially starches) with no major change in diet; ORT can be initiated and evaluated in the primary care office (to prevent hospitalization)
|
|
Inflammatory Diarrhea
- Clinical presentation - Site of involvement - Causes (typical) - Fecal leukocytes - Further diagnostic evaluation |
- Bloody, small-volume diarrhea; lower left quadrant abdominal cramps; may be febrile and toxic
- Colon - Shigella, some Salmonella species, Helicobacter jejuni, Yersinia, invasive or hemorrhagic E. coli, Campylobacter, Clostridium dificil, Ameba histolytica - + LE - further investigation indicated |
|
Non-Inflammatory Diarrhea
- Clinical presentation - Site of involvement - Causes (typical) - Fecal leukocytes - Further diagnostic evaluation |
- Large-volume watery diarrhea;
may have nausea, vomiting, cramps - Small intestine - Viruses, Vibrio, Enterotoxigenic Escherichia coli (ETEC) and other enterotoxin-producing bacteria, Giardia, Cryptosporidium, Cyclospora, Norwalk, Rotavirus, drugs. - negative LE - If severely volume depleted or toxic, or if lasts > 2 weeks |
|
Name the most common organism causing traveler's diarrhea
|
E. coli (various pathogenic mechanisms – mostly ETEC)
|
|
Understand the evidence behind the use of probiotics and the treatment/prevention
of antibiotic-induced diarrhea. |
Probiotics that contain species of Lactobacillus or Saccharomyces decrease the
likelihood of diarrhea from antibiotics in children or adults (absolute risk reduction: 3 to 23 percent; NNT: 10). Tell patients to look for these products in the "diarrhea section" of the pharmacy. A typical dosage is 5 to 10 billion viable organisms administered three to four times a day. The probiotics should be separated from the antibiotics by a couple of hours. (Level of Evidence: 1a) |
|
Name a vaccine now available to reduce the disease burden of infectious diarrhea.
|
Rotavirus is the leading recognized cause of diarrhea-related illness and death
among infants and young children. Every year, rotavirus is associated with 25 million clinic visits, 2 million hospitalizations, and more than 600,000 deaths worldwide among children younger than five years of age. Earlier vaccines were withdrawn because of association with intussusceptions. Two oral doses of the new live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteritis from any cause, and were not associated with an increased risk of intussusception. |